Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study by Schuster, Cornelia et al.
RESEARCH ARTICLE
Expression of Heat Shock Protein 27 in
Melanoma Metastases Is Associated with
Overall Response to Bevacizumab
Monotherapy: Analyses of Predictive Markers
in a Clinical Phase II Study
Cornelia Schuster1, Lars A. Akslen1,2*, Oddbjørn Straume3,4*
1 Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen,
Norway, 2 Department of Pathology, Haukeland University Hospital, Bergen, Norway, 3 Department of
Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway, 4 Centre for Cancer
Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
*Oddbjorn.straume@helse-bergen.no (OS); lars.akslen@k1.uib.no (LAA)
Abstract
The aim of this study was to identify potential predictive biomarkers in 35 patients with meta-
static melanoma treated with anti-angiogenic bevacizumab monotherapy in a clinical phase
II study. The immunohistochemical expression of various angiogenic factors in tissues from
primary melanomas and metastases as well as their concentration in blood samples were
examined. Strong expression of Heat Shock Protein 27 (HSP27) in metastases correlated
significantly with complete or partial response to bevacizumab (p = 0.044). Furthermore,
clinical benefit, i.e., complete or partial response or stable disease for at least 6 months,
was more frequent in patients with strong expression of HSP27 in primary tumors (p =
0.046). Tissue expression of vascular endothelial growth factor (VEGF-A), its splicing vari-
ant VEGF165b or basic fibroblast growth factor (bFGF) did not correlate with response, and
the concentration of HSP27, VEGF-A or bFGFmeasured in blood samples before treatment
did not show predictive value. Further, microvessel density, proliferating microvessel den-
sity and presence of glomeruloid microvascular proliferations were assessed in sections of
primary tumors and metastases. Microvessel density in primary melanomas was signifi-
cantly higher in patients with clinical benefit than in non-responders (p = 0.042). In conclu-
sion, our findings suggest that strong HSP27 expression in melanoma metastases predicts
response to bevacizumab treatment.
Trial Registration
ClinicalTrials.gov NCT00139360
PLOSONE | DOI:10.1371/journal.pone.0155242 May 11, 2016 1 / 15
a11111
OPEN ACCESS
Citation: Schuster C, Akslen LA, Straume O (2016)
Expression of Heat Shock Protein 27 in Melanoma
Metastases Is Associated with Overall Response to
Bevacizumab Monotherapy: Analyses of Predictive
Markers in a Clinical Phase II Study. PLoS ONE 11
(5): e0155242. doi:10.1371/journal.pone.0155242
Editor: Nikolas K. Haass, University of Queensland
Diamantina Institute, AUSTRALIA
Received: November 18, 2015
Accepted: April 25, 2016
Published: May 11, 2016
Copyright: © 2016 Schuster et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Support was provided by the Helse Vest
Research Fund: grant no. 911799 to OS, [http://www.
helse-vest.no/en/FagOgSamarbeid/Sider/default.
aspx] and the Norwegian Cancer Association: grant
no. 94070 to OS, [https://kreftforeningen.no/en/]. The
project was partly supported by the Research Council
of Norway through its Centres of Excellence funding
scheme, project number 223250 to LAA, CCBIO,
[http://www.forskningsradet.no/en/Home_page/
1177315753906]; Research Council of Norway, grant
Introduction
Cutaneous malignant melanoma (CMM) has shown an increasing incidence worldwide among
fair skinned populations during the last decades [1]. Five-year survival in metastatic disease is
still poor [2], and it remains to be seen whether new options like targeted treatment [3] or
immune checkpoint blockade [4] will improve long term survival rates. Acquired resistance [5]
and initial low response rates [6] are still major reasons for poor outcome, and predictive bio-
markers in addition to BRAFmutation status are needed [3].
Angiogenesis is an important cancer hallmark and treatment target [7, 8]. Preclinical mod-
els and clinical investigations have characterized primary melanomas and metastases as highly
vascularized [9–11]. Since vascular endothelial growth factor A (VEGF-A) plays a key role in
angiogenesis [12, 13] and is expressed in a high proportion of melanomas [9], we conducted a
clinical trial with bevacizumab monotherapy, a humanized monoclonal antibody that binds
specifically to VEGF-A, in patients with metastatic CMM [14]. As published previously, we
observed a clinical benefit rate of 31% [14], indicating that VEGF-A driven angiogenesis is
important in a subgroup of these patients. In addition, efficacy of different combinations
between bevacizumab and chemotherapy in patients with metastatic melanoma has been
reported [15–18]. Bevacizumab is also implemented in the treatment of various other solid
tumors but still no predictive biomarkers have been validated [19, 20].
In the present study, we aimed to explore potential predictive biomarkers known to be
involved in angiogenesis, and we focused on VEGF-A [12, 13], its splicing variant VEGF165b
that binds competitively to VEGFR-2 without phosphorylating pro-angiogenic pathways [21],
basic fibroblast growth factor (bFGF) [8] and Heat Shock Protein 27 (HSP27).
HSP27, a small heat shock protein, maintains cell survival under stressful conditions by
management of misfolded proteins and prevention of apoptosis [22, 23]. Furthermore, it
appears to play an important role in angiogenesis and in tumor cell migration as well as in
organization of the cytoskeleton [23, 24]. HSP27 expression is associated with impaired prog-
nosis in melanoma and other tumors as well as resistance to chemotherapy [23, 24]. Previous
studies from our group have identified HSP27 as important for tumor dormancy, angiogenesis
regulation and tumor progress in cutaneous melanoma and breast cancer [24]. Downregula-
tion of HSP27 in an angiogenic breast cancer cell line resulted in reduced secretion of VEGF-A
and bFGF, supporting a HSP27 dependent co-regulation of these factors. Furthermore, the
expression of HSP27-related transcription factors phospho-STAT3 and NFkB, involved in reg-
ulation of angiogenesis, were significantly reduced in xenograft tumors from HSP27 knock-
down cells [24]. Others showed increased secretion of VEGF after endothelial cells were
exposed to extracellular HSP27 [25].
Importantly, tissue based angiogenesis markers like microvessel density (MVD), proliferat-
ing microvessel density (pMVD), vascular proliferation index (VPI) and presence of glomeru-
loid microvascular proliferation (GMP) [11, 26–28] were studied. To our knowledge, the
present study is the first to indicate that strong tissue expression of HSP27 in melanoma metas-
tases predicts overall response to treatment with bevacizumab monotherapy. However, several
other angiogenic markers were not predictive in our study.
Material and Methods
Patients and study design
Thirty-five patients with metastatic melanoma were enrolled in an open-label, single arm phase
II study at Haukeland University Hospital, Norway, and were treated with bevacizumab 10 mg/
kg q14d until disease progression or intolerable toxicity (ClinicalTrials.gov: NCT00139360).
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Study design, eligibility criteria and clinical response data were reported earlier [14]. Fourteen of
the thirty-five patients were treated with dacarbazine before they were included in the study.
One of these patients received bevacizumab as third line treatment. Twenty-one patients were
treated with bevacizumab first line. This approach was based on the two-stage design for phase
II clinical trials by Simon [29]. As published previously [14], six of the thirty-five patients had
an overall response (OR), i.e. complete (CR) or partial response (PR), following treatment with
bevacizumab monotherapy. In addition, five more patients had stable disease (SD) for at least
six months. Thus, altogether 31% had a clinical benefit (CB), i.e. OR and SD. The study was con-
ducted in accordance with the ethical principles of the Declaration of Helsinki and the Interna-
tional Conference on Harmonization of Good Clinical Practice, and approved by the Regional
Ethics Committee (processing number: 05/329) and the Norwegian Medicines Agency.
Informed consent was signed by all patients before enrolment.
Tissue and blood samples
Paraffin embedded tissue of primary tumors was obtainable in 32 of 35 patients. The three
cases missing primary tumor tissue blocks represent one primary ocular melanoma treated by
radiation therapy, one unknown primary lesion, as well as one undiscoverable tissue block. All
primary melanomas were reclassified (LAA, CS) and characterized by the following histopath-
ologic features in hematoxylin and eosin-stained sections: histologic type by Clark, tumor
thickness by Breslow, mitotic rate, ulceration, Clark’s level of invasion, growth phase, vascular
invasion, tumor infiltrating lymphocytes and necrosis [30].
Tissue samples from metastases were available in all patients (35/35). The metastasis diag-
nosed closest to the date of inclusion (median 5 days) was chosen for further analysis if several
metastatic lesions were available. The material includes core needle biopsies (n = 17), mostly
taken from lung, liver and abdominal or pelvic organs, as well as excisional biopsies (n = 18)
from skin metastases or lymph nodes.
In addition, plasma and serum samples were taken before the first treatment with bevacizu-
mab (median: 2 days); altogether 29 plasma and 28 serum samples were available. EDTA blood
was immediately centrifuged at +4°C for 10 minutes at 1600xg, serum samples were processed
after clotting for 30 minutes at room temperature. All samples were stored at -20°C and ali-
quoted when used for analysis.
Immunohistochemistry
Tissue sections of 4–5 μmwere stained with primary antibodies for HSP27, VEGF-A, VEGF165b
and bFGF. Furthermore, double staining with anti-factor VIII (F-VIII) and Ki67 was performed
for angiogenesis assessment. After deparaffinizing in Xylene and different alcohol dilutions and
rehydration, heat mediated or enzymatic antigen retrieval was performed. Endogenous peroxi-
dase and alkaline phosphatase were blocked before incubation with the primary antibody fol-
lowed by incubation with appropriate HRP-EnVision (DAKO, K4011 or K4007). For staining
with HSP27 a secondary rabbit anti-goat antibody (Southern Biotech, Cat. no. 6164–01) was
used; for double staining, a secondary goat anti-mouse antibody (Southern Biotech, Cat. no.
1031–04) was used. Details are provided in Table 1. For negative controls, primary antibodies
were omitted or specific blocking peptides for HSP27, VEGF-A and bFGF were added. Tissues
from different cancer types were used as positive controls.
Evaluation of tissue staining results
Evaluation of HSP27, VEGF-A, VEGF165b and bFGF expression. All sections were sub-
jectively screened in a light microscope (Olympus CX31) at magnifications x40 and x100 to
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determine areas containing at least 50% tumor tissue; areas of ulceration or necrosis within the
tumor were avoided. Subsequently, staining intensity and the proportion of positive tumor
cells and endothelial cells (ECs) within the area of each high power field (HPF, x400) were
recorded using a semi-quantitative grading. Staining intensity was defined as absent (0), weak
(1), moderate (2) or strong (3). The proportion was rated as “no positive tumor cells” (0), “less
than 10% positive tumor cells” (1), “10–50% positive tumor cells” (2) or “more than 50% posi-
tive tumor cells” (3). The staining index (SI) is the product of intensity and area (range 0–9)
[9]; SI was used to determine cytoplasmic staining of VEGF-A and HSP27 and to record cyto-
plasmic and nuclear staining of VEGF165b and bFGF. The SI was evaluated by two observers
(CS, OS) blinded for response data.
Evaluation of microvessel density and glomeruloid microvascular
proliferations
Assessment of MVD and pMVD was done after dual staining (F-VIII/Ki67). F-VIII positive
ECs and microvessels were counted in three HPFs to assess MVD in primary tumors and
metastases. Sections were first screened at lower magnification (x40 and x100) for selection of
MVD hot-spot areas defined by high intensity of F-VIII [11, 26]. Areas of ulceration or necro-
sis within the tumor were avoided. Microvessels with co-expression of Ki67 in the nucleus and
F-VIII in the cytoplasm of ECs were defined as proliferating vessels. The pMVD was recorded
in the same three HPFs chosen for assessment of MVD. Ki67 positive nuclei within the lumen
or outside ECs were excluded. Both MVD and pMVD were reported as microvessel per mm2.
In addition, VPI was calculated as the ratio between pMVD and MVD (% of 100) [27].
Assessment of GMP was done after staining with F-VIII and hematoxylin counterstain.
GMPs were defined as the presence of focal glomerulus-like aggregates of related multilayered
F-VIII positive ECs with a minimum number of 15 cells. After screening the tumor at lower
magnification, GMPs were registered by x100 magnification in a maximum of four consecutive
HPFs within the area of highest density. Presence or absence of GMPs was finally reported
[28].
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed according to the manufacturer`s instructions for HSP27 (Enzo Life Sci-
ence, ADI-EKS-500) and for bFGF (R&D systems, DFB50) in serum samples as well as for
Table 1. Immunohistochemical stainingmethods.
Antibody Provider Epitope retrieval Dilution Incubation
HSP27 pAb sc-1048 (goat) Santa
Cruz
MW 6th sense 20 min,
pH6
1:100 30 min, RT
VEGF-A pAb sc-152 (rabbit) Santa
Cruz
MW 6th sense 20 min,
pH9
1:50 60 min, RT




FGF-2 pAb sc-1390 (rabbit) Santa
Cruz
Pressure cooker, pH9 1:50 60 min, RT
Von Willebrand Factor pAb A0082 (rabbit) Dako Proteinase K, 5 min 1:800 30 min, RT
Von Willebrand Factor pAb A0082 (rabbit) and Ki67 mAb (mouse)
M7240





pAb, polyclonal antibody; MW, microwave; RT, room temperature; mAb, monoclonal antibody.
doi:10.1371/journal.pone.0155242.t001
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VEGF-A165 (R&D systems, DVE00) in plasma and serum samples. Some samples were diluted
to fit within the absorbance of the HSP27-standard curve. Samples were run in duplicates.
Referring to the user`s manual, the MDD was less than 0.39 ng/ml for HSP27, 3.0 pg/ml for
bFGF and 9.0 pg/ml for VEGF. Results below these limits were considered to be zero.
Statistics
Statistical analyses were performed with SPSS, version 22 (SPSS Inc., Chicago, IL). For compar-
ison of two categorical variables, Pearson`s chi-square test was used. Since not all data followed
normal distribution, non-parametric tests were used for all analyses. Continuous and ordinal
variables were assessed by the Mann-Whitney U Test (MWT) or the Kruskal-Wallis Test
(KWT). Intratumoral protein expression, MVD or pMVD in primary tumors and metastases
as well as blood concentrations were independent variables when MWT was performed to cal-
culate the association with response or treatment line. Kruskal-Wallis test was used to calculate
the association between Breslow thickness and protein expression in primary melanomas
(independent variable). The association of various proteins and angiogenic factors between pri-
mary tumors and metastases were calculated by the paired Wilcoxon Test (pWT) by the
assumption that samples from the primary melanoma and the metastasis are matched pairs.
Strength and direction of correlations between two interval scaled continuous or ordinal vari-
ables or one of each type were calculated by Spearman`s rho correlation. The level of signifi-
cance was defined as p< 0.05. When continuous variables were categorized, the median was
used as cut-point if no other cut-point is defined. The statistical analyses of this study were per-
formed with pre-specified hypotheses for a limited number of intratumoral proteins related to
VEGF-A associated angiogenesis. Thus, we did not correct for multiple testing.
Results
Tissue expression of angiogenic factors
HSP27. HSP27 was expressed in the cytoplasm of melanoma cells in all primary tumors
and metastases. The median staining index (SI) was 6 for both primary tumors and metastases
(p = 0.74; paired Wilcoxon Test, (pWT)). Strong HSP27 expression in metastases was signifi-
cantly associated with overall response (OR) to treatment with bevacizumab monotherapy.
Median HSP27 SI for patients with OR was 7.5 compared to a median SI of 6 in patients with
stable disease (SD) or progressive disease (PD) (p = 0.044; Mann-Whitney U Test (MWT); Fig
1A and 1B; Table 2). Although some patients with HSP27 overexpression did not respond to
treatment, no one with low or absent HSP27 expression belonged to the OR-group. There
was also a trend for an association between HSP27 expression and OR in primary tumors
(p = 0.097; MWT), and HSP27 staining in primary melanomas was significantly associated
with CB from bevacizumab treatment (p = 0.046; MWT, S1 Table). Histologic features of the
primary tumors were not associated with HSP27 expression, nor with response. Median
HSP27 staining in metastases was significantly stronger within the group treated in first line
with bevacizumab compared to second line treatment (median SI 6 vs 3, p = 0.008; MWT, S2
Table).
VEGF-A. Cytoplasmic expression of VEGF-A was assessed separately in melanoma cells
and ECs in primary tumors and metastases. All primary melanomas, except one, expressed
VEGF-A in tumor cells (median SI = 5), and most metastases as well (33 of 35; median SI = 4).
However, the difference in VEGF-A SI between primary tumors and metastases was not signifi-
cant (p = 0.71; pWT). VEGF-A expression in metastases was neither significantly correlated to
OR (Fig 2A and 2B) nor to CB (Table 3). Treatment outcome did not depend on VEGF-A
expression in primary tumors (S3 Table). VEGF-A expression in metastases did not correlate
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significantly with HSP27 expression in metastases. VEGF-A expression in primary tumors was
not associated with any of the histologic features. Median VEGF-A expression was significantly
stronger in metastases from patients treated with bevacizumab in first line compared to
patients treated in second line (median SI 6 vs 3 p = 0.016; MWT, S4 Table).
VEGF-A expression in tumor associated ECs was present in 21/32 (66%) of primary tumors
and 15/35 (43%) of metastases. There was no association between EC-VEGF-A expression
(primary melanoma or metastases) and response to treatment.
VEGF165b. Both cytoplasmic and nuclear expression of VEGF165b was observed in
tumor cells of all primary melanomas and metastases. The median cytoplasmic SI was similar
in primary tumors and metastases (p = 0.22; pWT) but the nuclear SI was significantly lower in
metastases (p = 0.045; pWT, S1 Fig). The expression level of VEGF165b in primary tumors or
metastases was not associated with response to treatment. No associations with histologic fea-
tures or expression of VEGF-A were observed.
Fig 1. HSP27 expression in metastases predicts overall response to treatment with bevacizumab. (A)
HSP27 expression in metastases grouped by treatment response. CR: complete clinical response, PR:
partial response, SD: stable disease, PD: progressive disease. (B) Examples for low, moderate and high
staining index for HSP27. Original magnification x630.
doi:10.1371/journal.pone.0155242.g001
Table 2. Descriptive data for HSP27 expression in metastases.
HSP27 expression in metastases Overall response (OR) No OR Clinical benefit (CB) No CB
Mean SIa +/-SEMb 7.2 +/- 0.9 5.0 +/- 0.4 6.3 +/- 0.8 4.9 +/- 0.4
Median SI* 7.5 6 6 5
Minimum SI 4 2 2 2
Maximum SI 9 9 9 9
Number of patients 6 29 11 24
* p = 0.044 (OR), p = 0.15 (CB);
Mann-Whitney U Test.
a: Staining index (SI);
b: Standard error of mean (SEM).
doi:10.1371/journal.pone.0155242.t002
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bFGF. Cytoplasmic bFGF expression was observed in 31/32 primary melanomas and all
metastases; nuclear bFGF expression was seen in 30/32 primary melanomas and 28/35 metas-
tases. The median nuclear SI was similar in primary tumors and metastases (p = 0.174; pWT)
but the cytoplasmic SI was significantly lower in metastases (p = 0.030; pWT, S2 Fig). There
was no association between expression of bFGF in primary melanomas or metastases and
response to treatment. Regarding histologic features, primary tumors with a mitotic rate< 1/
mm2 showed stronger cytoplasmic and nuclear expression of bFGF (p = 0.03 and p = 0.02;
MWT), and strong nuclear expression was associated with the absence of ulceration and lower
Breslow thickness (p = 0.014; MWT; p = 0.021; Kruskal-Wallis test (KWT)).
MVD, pMVD, VPI and GMP. Quantification of angiogenesis markers MVD, pMVD and
GMP was based on immunohistochemical staining of tumor associated ECs and proliferating
ECs. Median MVD was 89/mm2 (mean 90/mm2) in primary melanomas and 108/mm2 (mean
107/mm2) in metastases; thus, MVD was significantly higher in metastases than in primary
Fig 2. VEGF-A expression in metastases is not associated with overall response to bevacizumab. (A)
VEGF-A expression in metastases grouped by treatment response. CR: complete clinical response, PR:
partial response, SD: stable disease, PD: progressive disease. (B) Examples for low, moderate and high
staining index for VEGF-A. Original magnification x630.
doi:10.1371/journal.pone.0155242.g002
Table 3. Descriptive data for VEGF-A expression in metastases.
VEGF-A expression in metastases Overall response (OR) No OR Clinical benefit (CB) No CB
Mean SIa +/- SEMb 5.7 +/- 1.1 4.3 +/- 0.5 5.4 +/- 0.8 4.2 +/- 0.6
Median SI* 5 3 6 3
Minimum SI 3 0 2 0
Maximum SI 9 9 9 9
Number of patients 6 29 11 24
a: Staining index (SI);
b: Standard error of mean (SEM)
* p = 0.27 (OR), p = 0.30 (CB);
Mann-Whitney U Test.
doi:10.1371/journal.pone.0155242.t003
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melanomas (p = 0.031; pWT). High MVD in primary tumors predicted CB to treatment with
a median MVD of 103/mm2 in responders vs. 83/mm2 in non-responders respectively
(p = 0.042; MWT), (Fig 3A and 3B; S3 Fig). No significant association was present between
MVD in metastases and treatment response. However, high MVD in metastases was correlated
to strong VEGF-A expression (p = 0.025; r = 0.39; Spearman).
Median pMVD was significant lower in primary melanomas (3.6/mm2; mean 5.8/mm2)
than in metastases (8.9/mm2; mean 9.9/mm2) (p = 0.01; pWT). There was no association
between pMVD and treatment response. Also, median VPI was significantly lower in primary
melanomas (5.1; mean 6.1) than in metastases (7.8; mean 10.4) (p = 0.035; pWT). VPI was not
associated with treatment response. In primary tumors, strong VEGF-A expression was corre-
lated to higher levels of pMVD and VPI (p = 0.028 and p = 0.027; r = 0.39 for both; Spearman).
GMPs were present in 8/32 (25%) of primary melanomas and 4/34 (12%) of metastases.
Presence of GMPs (primary melanomas or metastases) did not predict response to treatment.
Concentrations of angiogenic factors in blood samples
HSP27 concentration in serum samples. All measurements of HSP27 concentration in
serum (sHSP27) were above minimal detectable dose (MDD) (median 7.07 ng/ml). sHSP27
concentration was not associated with response to treatment (S11 Table). Notably, there was
no association between sHSP27 concentration and tissue expression of HSP27 in metastases,
nor with VEGF-A tissue expression. High sHSP27 was correlated with high VEGF-A in plasma
and serum as well as with high bFGF in serum (p = 0.004; r = 0.52; p = 0.038; r = 0.39 and
p<0.001; r = 0.76; Spearman, respectively). Notably, median sHSP27 was nine fold higher in
patients treated with bevacizumab in second line compared with first line (p<0.001; MWT,
S12 Table). Further, high sHSP27 was related to high LDH at the time of inclusion (p = 0.039;
r = 0.39; Spearman). sHSP27 was not correlated to MVD, pMVD, VPI or GMP in metastases.
VEGF-A concentration in serum and plasma samples. The VEGF-A concentration was
above MDD in all serum samples (sVEGF, median 345 pg/ml) and in 23/29 plasma samples
(pVEGF, median 52 pg/ml). High VEGF-A concentration in serum was significantly correlated
to high VEGF-A concentration in plasma (p<0.001; r = 0.75; Spearman). VEGF concentrations
in serum or plasma were not associated with response to treatment (S11 Table). Furthermore,
there was no correlation to VEGF-A expression in metastases. Median pVEGF was almost
six fold higher in patients treated with bevacizumab in second line compared with first line
(p = 0.017; MWT, S12 Table). High sVEGF and pVEGF were associated with high bFGF
in serum (p = 0.029; r = 0.41 and p = 0.004; r = 0.52; Spearman) and high baseline LDH
(p = 0.018 and p = 0.032; r = 0.4; for both, Spearman). There were no significant correlations
between VEGF concentrations in blood samples and tissue based angiogenesis markers (MVD,
pMVD, VPI, GMP) in metastases.
bFGF in serum. The bFGF concentration in serum (s-bFGF) was above MDD in 21/28
samples (median 7.8 pg/ml). The concentration of bFGF was not associated with response to
treatment (S11 Table). High s-bFGF was correlated to high sHSP27 and high plasma and
serum VEGF (see above). bFGF concentration in serum was not associated with expression
of any tissue markers in metastases including MVD, pMVD, VPI or GMP status. Notably,
median bFGF was significantly higher in serum samples from patients treated in second line
(p = 0.002; MWT, S12 Table).
Discussion
Several attempts to identify biomarkers of response to bevacizumab or other anti-angiogenic
drugs were recently reviewed by Lambrechts et al. [19]. Validation of potential predictive
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biomarkers for anti-angiogenic treatment is important to avoid severe side-effects among
patients without benefit, and to define treatment indications for optimized and personalized
medicine. Since angiogenesis is a complex and dynamic process involving many different
growth factors, cytokines and interactions with the stroma [31], there is a challenge to identify
individual predictive markers.
Multiple angiogenic factors have been investigated in randomized trials for various cancers
[19]. Still, none are currently established as predictive markers. The role of VEGF-A and differ-
ent VEGF-A SNPs as response predictors has been investigated in clinical trials of bevacizu-
mab. The results are inconsistent, and although associations to improved progression free [32]
or overall survival [33] were reported in some trials, none of these markers have been firmly
validated [19, 34].
So far, treatment induced hypertension appears to predict clinical benefit in patients treated
with anti-angiogenic drugs as reported in metastatic renal cell cancer [35] and metastatic mela-
noma [14]. In contrast, early hypertension did not predict treatment response in metastatic
colorectal cancer when bevacizumab was given in combination with chemotherapy [36].
Here, as a novel finding, strong tissue expression of HSP27 in melanoma metastases was
associated with overall response (OR) to bevacizumab monotherapy. Strong expression of
HSP27 in metastases characterized all patients with OR, and no patients with weak or absent
HSP27 expression were among the responders. Other studies have identified strong HSP27
expression as a prognostic marker for poor outcome in various solid tumors [37–39], and
increased intratumoral expression is associated with more advanced tumor stages in ovarian
cancer [40]. Furthermore, strong HSP27 expression in vitro and in vivo is associated with resis-
tance to chemotherapy and its downregulation increased sensitivity to treatment [40–43].
HSP27, which is phosphorylated and activated in cells under stressful conditions like hypoxia,
is involved in angiogenesis by regulating expression and secretion of VEGF as previously
reported [24, 25]. Straume et al. investigated the mechanistic role of HSP27 in angiogenesis in
Fig 3. Highmicrovessel density (MVD) in primary tumors predicts clinical benefit to treatment with
bevacizumab. (A) MVD in primary melanomas grouped by treatment response. Median MVD in primary
melanomas is significantly higher in patients with clinical benefit. CR: complete clinical response, PR: partial
response, SD: stable disease, PD: progressive disease (B) Immunohistochemical staining showing high and
low MVD. Original magnification x100.
doi:10.1371/journal.pone.0155242.g003
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various models. Knockdown of HSP27 in an angiogenic breast cancer cell line resulted in phe-
notypic non-angiogenic and microscopic xenograft tumors. Gene expression analysis showed
reduced expression of HSP27 as well as of VEGF-A and bFGF [24]. In addition, strong expres-
sion of HSP27 was associated with decreased survival in melanoma and breast cancer [24]. Our
present finding that strong expression of HSP27 in melanoma metastases is associated with
response to anti-VEGF therapy, is in support of HSP27 being a negative prognostic factor and
a predictive indicator for treatment response. The reason for this might be that increased
HSP27 expression identifies an aggressive melanoma phenotype with an active VEGF depen-
dent angiogenesis that is more sensitive to anti-VEGF treatment.
Although we found a strong correlation between sHSP27 and pVEGF, sVEGF as well as s-
bFGF in blood samples taken before treatment with bevacizumab, there was no association
between tissue expression of HSP27 in metastases and sHSP27, similar to a previous study on
breast cancer [44], and no relationship between blood levels of these factors and response to
treatment.
Apart from the significant correlation between high MVD in primary tumors and clinical
benefit, we observed no significant associations between VEGF, bFGF (in tissues or blood sam-
ples), VEGF165b or tissue based angiogenesis markers and response to treatment. This is in
line with the disappointing conclusions from multiple studies of anti-angiogenesis treatment
and biomarkers in various cancers [19, 34, 45].
The associations of all assessed intratumoral proteins and angiogenic factors between the
primary tumors and metastases were investigated. The median protein expression was similar
in primary tumors and metastases except for cytoplasmic bFGF and nuclear VEGF165b. Con-
trary, the median of MVD, pMVD and VPI was significantly higher in metastases. Based on
these findings, a biopsy of the metastatic lesion should be used for investigations of predictive
factors.
There was a lack of consistent associations between tissue expression of angiogenesis mark-
ers and their levels observed in plasma or serum samples. These findings might be explained by
changing tumor-stroma interactions and heterogeneity in primary tumors and metastases, as
well as the possibility of clonal evolution and tumor progression in metastatic tumors. Under
physiologic angiogenesis, i.e. during wound healing, an inverse relation between local and sys-
temic levels of angiogenic factors has been repeatedly observed [46, 47]. These changes might
in part explain the challenges in robust quantification of dynamic growth factors, especially
ligands like VEGF and bFGF, during cancer progression and treatment.
Since VEGF-A is a key player in angiogenesis and a specific treatment target on this trial, we
also looked at associations between VEGF-A and other markers. VEGF-A tissue expression
was significantly associated with microvessel proliferation (pMVD and VPI) in primary mela-
nomas, and with overall microvessel density (MVD) in metastases. Taken together, our find-
ings support an important role of VEGF-A in melanoma angiogenesis and progression as
previously indicated [28]. Nevertheless, none of these angiogenesis markers were associated
with blood levels of VEGF. Our results are in line with findings by Byrne et al. who reported
that VEGF expression in primary breast cancer patients was significantly associated with MVD
but not with VEGF concentration in platelet-depleted plasma [48].
The intratumoral expression of some proteins as well as their blood concentrations differed
significantly between the patients treated with bevacizumab in first line and second line.
Median HSP27 expression in tumor cells in metastases was significantly reduced in patients
treated with DTIC in first line followed by bevacizumab when compared to the group of
patients treated with bevacizumab in first line. Most responders were found in the latter group
[14]. The reason why HSP27 expression was significantly reduced in patients treated with
DTIC in first line is not clear. Experimental studies have shown that exposure to both single
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and repeated doses of DTIC could select for a more aggressive melanoma phenotype through
induction of VEGF and interleukin 8 by mechanisms other than HSP27 [49]. Thus, pretreat-
ment with DTIC in first line might have selected a more complex angiogenic phenotype, more
resistant to the specific inhibition of VEGF-A with bevacizumab.
Contrary, serum HSP27 was nine fold higher in patients treated with DTIC in first line fol-
lowed by bevacizumab. Although, the mechanism of HSP27 secretion is not yet completely
understood, release from necrotic cells after exposure to chemotherapy could contribute to
increased extracellular levels of HSP27 [50]. Similarly, to sHSP27, the concentrations of
pVEGF and s-bFGF were significantly higher in patients treated with DTIC in first line. This is
again pointing to the inverse relation between local and systemic levels of angiogenic factors,
and suggests that the increased systemic levels of these factors might have other sources than
the tumor cells [13].
There are limitations to the present study. One is the low number of patients included, with
a relative lack of statistical power. Another problem is the limited amount of tissue available
for analysis especially from some metastatic lesions. It is well known that tumor angiogenesis is
not evenly distributed and tends to occur in hot-spot areas. The sampling bias might therefore
reduce sensitivity and might have impact on the angiogenesis quantification by markers like
MVD and pMVD, as well as on the representativeness of intratumoral protein expression,
especially regarding small samples from metastatic lesions. However, metastatic melanoma tis-
sue was sampled in accordance with contemporary practice. It remains to be investigated if
such tissue samples are sufficiently robust for predictive purposes. On the other hand, since no
chemotherapy was given concomitantly, the findings are based on the effects of a single drug.
Another advantage is the availability of matched primary tumors and metastases as well as
serum and plasma samples. In addition, histologic features of the primary tumors as well as
clinical features and follow-up data, including response information, were available. Neverthe-
less, because of the low number of patients, limited amount of tissue, in some cases of core nee-
dle biopsies, as well as the lack of a randomized control group, the results must be interpreted
carefully.
In conclusion, our data indicate that strong expression of HSP27 protein in melanoma
metastases predicts overall response to bevacizumab monotherapy in patients with metastatic
melanoma. In contrast, multiple other angiogenesis markers, examined in tissues and blood
samples, showed no relationship with treatment response. Further randomized studies are nec-
essary to validate our findings.
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a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.097 (OR), p=0.046 (CB); Mann-Whitney U Test.  
 
S2 Table. Descriptive data for HSP27 expression in  







Mean SIa +/- SEMb 6.2 +/- 0.5 4.1 +/- 0.5 
Median SI* 6 3 
Minimum SI 3 2 
Maximum SI 9 9 
Number of patients 21 14 
a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.008; Mann-Whitney U Test 
 
S3 Table. Descriptive data for VEGF-A expression in primary tumors 
VEGF-A expression 
in primary tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean SIa +/- SEMb 5.2 +/- 1.0 5.1 +/- 0.5 5.6 +/- 0.6 4.8 +/- 0.6 
Median SI* 5 5 6 4 
Minimum SI 3 0 3 0 
Maximum SI 9 9 9 9 
Number of patients 6 26 11 21 
a: Staining index (SI); b: Standard error of mean (SEM) 




in primary tumors 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean SIa +/- SEMb 6.5 +/- 0.5 5 +/- 0.3 6.3 +/- 0.5 4.8 +/- 0.3 
Median SI* 6 6 6 6 
Minimum SI 6 2 3 2 
Maximum SI 9 9 9 6 
Number of patients 6 26 11 21 
S4 Table. Descriptive data for VEGF-A expression in metastases according to line of 
treatment 






Mean SIa +/- SEMb 5.4 +/- 0.5 3.2 +/- 0.7 
Median SI* 6 3 
Minimum SI 2 0 
Maximum SI 9 9 
Number of patients 21 14 
a: Staining index (SI); b: Standard error of mean (SEM) 
* p=0.016; Mann-Whitney U Test. 
 
S5 Table. Descriptive data for microvessel density (MVD) in primary tumors 
MVD in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean MVD +/- SEMa 89.2 +/- 10.3 90.1 +/- 8.4 101.7 +/- 8.5 83.8 +/- 9.6 
Median MVD* 94.9 88.7 102.8 83.3 
Minimum MVD 53.2 23.1 53.2 23.1 
Maximum MVD 120.6 244.7 143.6 244.7 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.62 (OR), p=0.042 (CB); Mann-Whitney U Test.  
 
S6 Table. Descriptive data for microvessel density (MVD) in metastases 
MVD in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean MVD +/- SEMa 104.6 +/- 18.2 107.1 +/- 10.4 93.4 +/-14.7 112.4 +/- 11.2 
Median MVD* 97.5 108.2 86.0 115.3 
Minimum MVD 60.3 24.8 28.4 24.8 
Maximum MVD 154.3 212.8 154.3 212.8 
Number of patients 6 27 10 23 








S7 Table. Descriptive data for proliferating microvessel density (pMVD) in primary tumors 
pMVD in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean pMVD +/- 
SEMa 5.0 +/- 2.0 6.0 +/- 1.4 5.2 +/-1.4 6.2 +/- 1.6 
Median pMVD* 4.4 3.5 3.6 3.6 
Minimum pMVD 0 0 0 0 
Maximum pMVD 14.2 30.1 14.2 30.1 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.98 (OR), p=0.85 (CB); Mann-Whitney U Test.  
 
S8 Table. Descriptive data for proliferating microvessel density (pMVD) in metastases 
pMVD in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean pMVD +/- 
SEMa 15.7 +/- 5.0 8.6 +/- 1.5 9.8 +/- 3.8 9.9 +/- 1.6 
Median pMVD* 11.53 7.1 5.3 8.9 
Minimum pMVD 5.3 0 0 0 
Maximum pMVD 35.5 31.9 35.5 31.9 
Number of patients 6 27 10 23 
a: Standard error of mean (SEM); * p=0.16 (OR), p=0.48 (CB); Mann-Whitney U Test.  
 
S9 Table. Descriptive data for vascular proliferation index (VPI) in primary tumors 
VPI in primary 
tumor 
Overall 
response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean VPI +/- SEMa 5.7 +/- 1.9 6.2 +/- 1.2 5.3 +/- 1.4 6.5 +/- 1.4 
Median VPI* 4.6 5.1 4.1 5.3 
Minimum VPI 0 0 0 0 
Maximum VPI 13.6 21.6 13.6 21.6 
Number of patients 6 26 11 21 
a: Standard error of mean (SEM); * p=0.98 (OR), p=0.82 (CB); Mann-Whitney U Test.  
 
S10 Table. Descriptive data for vascular proliferation index (VPI) in metastases 
VPI in metastases Overall response (OR) No OR 
Clinical 
benefit (CB) No CB 
Mean VPI +/- SEMa 15.5 +/- 3.8 9.2 +/- 1.8 10.1 +/- 3.2 10.5 +/- 2.0 
Median VPI* 15.4 7.6 7.8 7.8 
Minimum VPI 3.5 0 0 0 
Maximum VPI 29.0 46.2 29.0 46.2 
Number of patients 6 27 10 23 
a: Standard error of mean (SEM); * p=0.11 (OR), p=0.83 (CB); Mann-Whitney U Test.  
S11 Table. Concentrations of HSP27, VEGF-A and bFGF in blood samples according to overall response 
a: Standard error of mean (SEM); p=0.49 (HSP27), p=0.28 (VEGFA, plasma), p=0.72 (VEGF-A, serum), p=0.89 (bFGF); *Mann-Whitney U test.  
 
 
S12 Table. Concentrations of HSP27, VEGF-A and bFGF in blood samples according to line of treatment 
a: Standard error of mean (SEM); p<0.0005 (HSP27), p=0.017 (VEGFA, plasma), p=0.072 (VEGF-A, serum), p=0.002 (bFGF);  



















Overall response yes no yes no yes no yes no 
Mean 30.6 14.1 72.2 114.1 342.0 391.3 7.1 7.1 
SEMa 23.9 3.0 56.7 29.5 121.9 66.4 2.6 0.9 
Median* 4.8 7.4 14.0 74.0 255.5 381.0 7.2 8.2 
Minimum 0.9 1.1 0 0 66.0 18.0 0 0 
Maximum 149.0 49.2 353.0 615.0 901.0 1110.0 15.4 11.8 
Number of 




















st line 2nd line 1st line 2nd line 1st line 2nd line 1st line 2nd line 
Mean 7.1 29.8 53.3 169.6 267.1 511.9 4.6 10.0 
SEMa 3.1 10.5 18.3 48.5 49.2 100.3 1.2 0.7 
Median* 2.5 22.4 20 118.0 189.0 415.0 6.7 9.5 
Minimum 0.9 6.0 0 0 18.0 113.0 0 7.3 
Maximum 49.2 149.0 214 615.0 547.0 1110.0 10.7 15.4 
Number of 
samples 15 13 16 13 15 13 15 13 

